Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12704030 | 0.82 | NR1H2 (0.32) | NR1H2NR1H3 | |
| SCHEMBL14736855 | 0.79 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2MEN1 | |
| SCHEMBL9845206 | 0.79 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2MEN1 | |
| SCHEMBL12704099 | 0.78 | CYP3A4 (0.30) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL12587456 | 0.78 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2SMYD2MEN1 | |
| SCHEMBL13577566 | 0.78 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL12772162 | 0.78 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2SMYD2MEN1 | |
| SCHEMBL16350794 | 0.78 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2SMYD2MEN1 | |
| SCHEMBL12586595 | 0.77 | SLC6A2 (0.32) | NR1H2NR1H3CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL705925 | 0.76 | RIPK1 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | FLT4, VEGFA, FLT1 | NR1H2 889/4885NR1H3 1022/4885CYP3A4 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.